Management of Epistaxis in Congenital Heart Disease with Pulmonary Arterial Hypertension
In patients with congenital heart disease and pulmonary arterial hypertension presenting with epistaxis, apply firm sustained compression to the lower third of the nose for at least 5 minutes as first-line treatment, followed by anterior rhinoscopy to identify the bleeding source, with extreme caution regarding any interventions that could trigger acute hemodynamic decompensation or pulmonary hypertensive crisis 1, 2.
Critical Risk Stratification
These patients represent a high-risk population requiring specialized management. The combination of CHD-PAH creates vulnerability to acute perioperative decompensation, with any hemodynamic perturbation potentially triggering right-sided heart failure 2. The 2025 anesthesia guidelines explicitly classify severe PAH as a high-risk condition requiring expert center management 2.
Immediate Assessment Priorities
Determine bleeding severity and hemodynamic stability first:
- Severe bleeding indicators: Duration >30 minutes in 24 hours, bleeding from both nostrils or mouth, signs of hypovolemia (tachycardia, syncope, orthostatic hypotension) 1
- High-risk features: Hypertension, anticoagulant/antiplatelet therapy, recurrent episodes 3
- Hemodynamic compromise: Any evidence of decreased cardiac output, systemic hypotension, or metabolic acidemia requires immediate hospital-level care 4
If hemodynamically unstable or severe bleeding: Direct immediately to emergency department or hospital setting 1. These patients cannot be managed in routine ambulatory settings.
Stepwise Management Algorithm
Step 1: Initial Control (All Settings)
Apply firm sustained digital compression to the lower third of the nose for minimum 5 minutes 1. This is the simplest, most effective first intervention with minimal hemodynamic impact. During compression, obtain critical history:
- Current anticoagulation/antiplatelet medications
- Baseline PAH severity and functional class
- Recent changes in PAH-specific therapies (phosphodiesterase-5 inhibitors, endothelin receptor antagonists) 5
- Personal or family bleeding history
Step 2: Source Identification (After Stabilization)
Perform anterior rhinoscopy after removing any blood clot to identify the bleeding site 1. If the source is not clearly anterior, nasal endoscopy should be performed or the patient referred to someone who can perform it 1.
Step 3: Definitive Treatment Based on Location
For anterior bleeding with identified source:
- Anesthetize the bleeding site
- Restrict cautery application only to the active or suspected bleeding site 1
- Avoid excessive manipulation that could trigger vagal responses or hemodynamic instability
For posterior or uncontrolled bleeding:
- Treat with nasal packing 1
- Consider this a higher-risk intervention requiring monitoring for:
Step 4: Specialized Considerations for CHD-PAH
Critical pitfall: Standard epistaxis interventions can precipitate pulmonary hypertensive crisis in this population. The immediate postoperative PAH literature demonstrates that even minor perturbations can cause marked PVR increases, leading to acute right-sided heart failure, decreased cardiac output, and cardiovascular collapse 4.
Avoid or use extreme caution with:
- Deep nasal packing (increases airway resistance)
- Aggressive suctioning or manipulation
- Procedures requiring sedation without appropriate monitoring
- Any intervention causing pain, anxiety, or Valsalva maneuvers
Anticoagulation Management Nuance
Do not automatically reverse anticoagulation in patients with Eisenmenger syndrome or complex CHD-PAH. These patients often have:
- Paradoxical emboli risk through right-to-left shunts 4, 6
- Secondary erythrocytosis requiring careful balance 6
- Thrombotic complications from chronic hypoxemia
Anticoagulation decisions require consultation with the patient's ACHD cardiologist before modification 5.
When to Involve Specialized Care
Mandatory ACHD cardiology involvement for 5:
- Any patient with anatomically moderate or complex CHD
- Eisenmenger syndrome (all cases)
- PAH with pulmonary vascular resistance >3 Wood units 6
- Need for procedural intervention beyond simple cautery
- Recurrent epistaxis requiring repeated interventions
Transfer to specialized center if 2:
- Interventional procedures required (surgical ligation, embolization)
- Hemodynamic instability develops
- Failure of conservative measures in high-risk anatomy
Monitoring Requirements
During and after treatment, monitor for:
- Oxygen saturation changes (critical in patients with shunts)
- Heart rate and blood pressure trends
- Signs of right heart strain or decompensation
- Respiratory distress or increased work of breathing
Post-treatment follow-up must address:
- Underlying PAH optimization (many patients are undertreated) 7
- Blood pressure control if hypertensive 3
- Review of PAH-specific medications that may affect bleeding risk
- Preventive measures (humidification, nasal saline, avoiding trauma)
Key Clinical Pearls
The mortality rate in hospitalized epistaxis patients can reach 7.8%, with highest risk in patients with vascular complications 8. In CHD-PAH populations, mortality is substantially elevated (35.7% by age 50 in recent registries) 7, making any acute complication potentially life-threatening.
Most important principle: Prioritize hemodynamic stability over definitive bleeding control. A patient with controlled epistaxis but precipitated right heart failure has a worse outcome than one with minor ongoing bleeding and stable hemodynamics. The goal is gentle, minimally invasive control that avoids triggering the cascade of increased PVR, right ventricular failure, and systemic decompensation that characterizes acute PAH crises in this population 2, 4.